Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ocrelizumab vs fingolimod in pediatric relapsing-remitting multiple sclerosis
2020-004128-41Phase 3Active
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Ocrelizumab arm with Fingolimod arm (2 arms). Primary endpoint: Protocol-defined annualized relapse rate (ARR). Started Jul 2021; status: active.
02
Drugs
ocrelizumabfingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2020-004128-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004128-41.